The efficacy and safety of epirubicin and cyclophosphamide combined with pyrotinib in neoadjuvant treatment for HER2-positive breast cancer: A real-world study

Overview of attention for article published in Frontiers in oncology, January 2023

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Good Attention Score compared to outputs of the same age and source (71st percentile)

Mentioned by

twitter: 3 X users

Readers on

mendeley: 6 Mendeley

Summary X

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 23,852 followers.

The efficacy and safety of epirubicin and cyclophosphamide combined with pyrotinib in neoadjuvant treatment for HER2-positive breast cancer: A real-world study https://t.co/TA3CXLMRI0

20 Feb 2023

Reply Repost Favourite

The efficacy and safety of epirubicin and cyclophosphamide combined with pyrotinib in neoadjuvant treatment for HER2-positive breast cancer: A real-world study https://t.co/3hyFxonAQu https://t.co/2heQz0RHX4

31 Jan 2023

Reply Repost Favourite

New research: The efficacy and safety of epirubicin and cyclophosphamide combined with pyrotinib in neoadjuvant treatment for HER2-positive breast cancer: A real-world study: Purpose Long-term survival benefit of anthracyclines for human… https://t.co/hsA

31 Jan 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.